What is Poseida Therapeutics?
Founded in 2014 and headquartered in California, Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation therapies for patients with high unmet medical needs. The company specializes in addressing complex conditions, including various forms of blood cancers and solid tumors. By leveraging advanced gene engineering technologies, Poseida aims to deliver durable, curative treatments that improve patient outcomes. Its market position is defined by a robust intellectual property portfolio and a commitment to precision medicine, positioning the firm as a significant player in the evolving oncology and genetic medicine sectors.
How much funding has Poseida Therapeutics raised?
Poseida Therapeutics has raised a total of $566.3M across 8 funding rounds:
Series A
$23M
Private Equity
$11.2M
Unspecified
$19.8M
Series B
$30.5M
Series C
$142M
Series D
$110M
Stock Offering
$204.8M
Share Placement
$25M
Series A (2015): $23M with participation from Malin Corporation Plc
Private Equity (2017): $11.2M, investors not publicly disclosed
Unspecified (2017): $19.8M supported by California Institute of Regenerative Medicine
Series B (2018): $30.5M featuring Longitude Capital, Malin Corporation plc, Vivo Capital, and Tavistock Life Sciences
Series C (2019): $142M backed by Malin Corporation plc, Perceptive Advisors, Aisling Capital, Pentwater Capital Management, Novartis Pharma, Longitude Capital, Boxer Capital, and Vivo Capital
Series D (2020): $110M with participation from Adage Capital Management, Fidelity Management Research Company, and Schonfeld Strategic Advisors
Stock Issuance/Offering (2020): $204.8M, investors not publicly disclosed
Share Placement (2023): $25M supported by Astellas Venture Management
Key Investors in Poseida Therapeutics
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies, with over $1.8 billion in assets.
Vivo Capital
Vivo Capital, founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
What's next for Poseida Therapeutics?
With the recent $25M strategic investment, Poseida Therapeutics is well-positioned to accelerate its clinical development programs and expand its therapeutic reach. The company is expected to prioritize the advancement of its lead candidates through critical trial phases, while simultaneously optimizing its manufacturing processes to support future commercial scalability. As the firm transitions into a more mature lifecycle stage, the focus will likely shift toward strategic partnerships and the potential for long-term value creation in the high-growth gene therapy market. Continued institutional backing provides the necessary runway to sustain innovation in the face of rigorous regulatory and competitive pressures.
See full Poseida Therapeutics company page
